Peptide Reference
Exenatide
Exenatide
The first GLP-1 receptor agonist approved (Byetta), derived from Gila monster venom. Available as twice-daily or once-weekly (Bydureon) formulation.
Status
approved
Category
weight loss
Typical cost
$600-900/month (brand)
Mechanism
Activates GLP-1 receptors from exendin-4, a peptide found in Gila monster venom. Stimulates insulin secretion, suppresses glucagon, reduces appetite.
Potential benefits
- Established safety profile
- Moderate weight loss 3-5%
- Good glycemic control
- Twice daily or weekly options
Reported side effects
- Nausea
- Vomiting
- Injection site reactions
- Less weight loss than newer GLP-1s
Common dosing references
subcutaneous
5-10mcg · 2x daily
Ongoing
subcutaneous (Bydureon)
2mg · Weekly
Ongoing
Research notes
Exenatide diabetes and weight
2005
Demonstrated glycemic improvements and modest weight loss in type 2 diabetes
Regulatory and sourcing notes
FDA-approved (Byetta twice daily, Bydureon weekly). Older GLP-1 with extensive safety data.
Prescription required. Older GLP-1 with longest safety history. Less potent for weight than semaglutide.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.
Related peptides